Parnax Lab
- Market cap
- ₹ 128 Cr.
- P/E
- 12.8x
- P/B
- 1.26x
- 52-week range
- 90 – 149.5
- ROE
- 14%
- ROCE
- 14%
- Dividend yield
- 0%
- Debt / equity
- 0.87
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Parnax Lab Limited is an India-based holding company. The Company is principally engaged in the business activities of manufacturing and export of pharmaceutical formulations. The Company operates through the trading of the pharmaceuticals and medicinal products segment. It is engaged in developing and delivering huge volumes of oral formulations, such as cough expectorants, antacids, antihistamines, multi-vitamins, enzyme preparations, pediatric formulations, special formulations for geriatrics, viscous products, suspensions, and others. Its product portfolio consists of pharmaceuticals, cosmetics, herbal, and nutraceuticals. Its cosmetics products include antidruf gel, EVE fairness acne care night cream for acne skin, EVE fairness scrub, and others. The Company provides companies with the service of developing the drug through Contract Research and Manufacturing Services (C.R.A.M.S) or manufacturing collaborations. The Company’s subsidiary is Naxpar Pharma Private Limited.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Parnax Lab against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)12.8 against a typical 34: cheaper than most peers (1st = cheapest).31st of 220
- Sales growth+6.4% against a typical +15.6% from a year earlier.127th of 197
- Profit growth−86.9% against a typical +18.9% from a year earlier.144th of 160
- Size₹ 128.5 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).138th of 199
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
Look closer
Rated D by Brickwork- No warnings from the agency.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| Brickwork | BWR D | — | 25 Aug 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 25 Aug 2026 | Reaffirmed | BWR D | — | Brickwork | ₹ 10.34 Cr. |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 43 | 51 | 46 | 50 | 48 | 40 | 49 | 53 | 63 | 63 | 70 | 57 |
| Expenses | 37 | 45 | 41 | 42 | 41 | 36 | 42 | 46 | 55 | 56 | 65 | 52 |
| Operating Profit | 5 | 6 | 6 | 9 | 7 | 4 | 7 | 7 | 8 | 7 | 5 | 4 |
| OPM % | 12.4% | 11.7% | 12.5% | 17.2% | 15% | 10.6% | 13.5% | 13.9% | 12.9% | 10.9% | 7% | 7.6% |
| Other Income | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | −0 | 2 | 0 |
| Interest | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 |
| Depreciation | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Profit before tax | 2 | 3 | 3 | 5 | 5 | 1 | 4 | 4 | 5 | 3 | 3 | 1 |
| Tax % | 20.1% | 25.9% | 19.4% | 26.3% | 29.8% | 16.7% | 26.1% | 26.5% | 30.3% | 16.6% | 27.1% | 28.3% |
| Net Profit | 2 | 2 | 2 | 4 | 3 | 1 | 3 | 3 | 4 | 3 | 2 | 0 |
| EPS in Rs | 1.63 | 1.9 | 1.95 | 3.47 | 2.97 | 1.05 | 2.54 | 2.85 | 3.16 | 2.36 | 1.9 | 0.37 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 13%
- 5 Years
- 23%
- 3 Years
- 14%
- TTM
- 32%
- 10 Years
- 18%
- 5 Years
- 105%
- 3 Years
- 14%
- TTM
- −7%
- 10 Years
- 14%
- 5 Years
- 37%
- 3 Years
- 11%
- TTM
- —
- 10 Years
- 11%
- 5 Years
- 15%
- 3 Years
- 15%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Parnax Lab | ₹ 102.30 | ₹ 128 Cr. | 12.8x | 1.3x | 14% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Prakash Mihir Shah
- Managing Director Cum Chief Executive Officer
- Binoy Baiju Shah
- Executive Director Cum Chief Financial Officer
- Preet Vijay Kukreja
- Compliance Officer, Company Secretary
Prices are delayed and for information only. Nothing on this page is investment advice.